Jump to content
RemedySpot.com

A comparison of the efficacy and safety of oral and intravenous fludarabine in chronic lymphocytic leukemia in the LRF CLL4 trial.

Rate this topic


Recommended Posts

Posted

BlankA comparison of the efficacy and safety of oral and intravenous fludarabine

in chronic lymphocytic leukemia in the LRF CLL4 trial.

CE Dearden, S s, M Else, D Catovsky, and P Hillmen

Cancer, December 14, 2010; .

Section of Haemato-Oncology, The Royal Marsden Hospital and The Institute of

Cancer Research, Sutton, UK.

BACKGROUND:: An oral formulation of fludarabine was introduced for use in

chronic lymphocytic leukemia in 2001 following studies demonstrating the

bioequivalence of a 40 mg/m(2) oral dose with a 25 mg/m(2) intravenous dose. We

assessed retrospectively the efficacy of these two routes of administration in

the LRF CLL4 trial. METHODS:: A total of 777 patients were randomized from

1999-2004 to receive fludarabine, alone or with cyclophosphamide, or

chlorambucil. In 2001, a protocol amendment allowed the oral formulation. There

were 117 assessable patients who received fludarabine intravenously and 252 who

received it orally. A total of 387 patients given chlorambucil acted as a

control group. RESULTS:: Patients given oral fludarabine were less likely to

receive the full dose (P = .0004) and experienced more, predominantly

gastrointestinal, toxicity. Progression-free survival (PFS) and overall survival

were not affected by the route of administration (PFS hazard ratio, 1.10; 95%

confidence interval, 0.87-1.40), but the overall rate of response to treatment

appeared to be lower with the oral formulation (P = .003). However, patients

recruited since 2001 were older (P = .03) and were more likely to have TP53

deletion, and response rates after 2001 were also lower in the chlorambucil

group. After excluding patients with TP53 deletion, no significant difference in

outcome was attributable to the route of administration. CONCLUSIONS:: Although

the LRF CLL4 data suggest no important difference in the effectiveness of oral

compared with intravenous fludarabine, randomized trials are needed to reliably

evaluate this comparison, particularly in combination with rituximab. Meanwhile,

it is important to monitor compliance and gastrointestinal side effects with the

oral route and to switch to intravenous therapy if a reduced dose is being

received. Cancer 2011. ? 2010 American Cancer Society.

PMID: 21157963

Join the conversation

You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

Loading...
×
×
  • Create New...